Four development programs are neck-and-neck in the race to bring a calcitonin gene-related peptide (CGRP) inhibitor to market, and Amgen Inc. is the first company – with its partner Novartis AG – to report positive Phase III results for their biologic erenumab (AMG 334) in episodic headache sufferers.
Speed of development is key, because Amgen and Novartis may have to be the first anti-CGRP developers to commercialize a...